- Home
- AGYS vs RYTM Comparison
AGYS vs RYTM Comparison
Compare AGYS & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGYS
- RYTM
- Stock Information
- Founded
- AGYS 1963
- RYTM 2008
- Country
- AGYS United States
- RYTM United States
- Employees
- AGYS N/A
- RYTM N/A
- Industry
- AGYS EDP Services
- RYTM Biotechnology: Pharmaceutical Preparations
- Sector
- AGYS Technology
- RYTM Health Care
- Exchange
- AGYS Nasdaq
- RYTM Nasdaq
- Market Cap
- AGYS 2.9B
- RYTM 3.1B
- IPO Year
- AGYS N/A
- RYTM 2017
- Fundamental
- Price
- AGYS $121.81
- RYTM $54.54
- Analyst Decision
- AGYS Strong Buy
- RYTM Strong Buy
- Analyst Count
- AGYS 5
- RYTM 10
- Target Price
- AGYS $146.00
- RYTM $66.90
- AVG Volume (30 Days)
- AGYS 205.9K
- RYTM 580.8K
- Earning Date
- AGYS 01-21-2025
- RYTM 02-20-2025
- Dividend Yield
- AGYS N/A
- RYTM N/A
- EPS Growth
- AGYS 628.86
- RYTM N/A
- EPS
- AGYS 3.42
- RYTM N/A
- Revenue
- AGYS $254,579,000.00
- RYTM $112,530,000.00
- Revenue This Year
- AGYS $21.10
- RYTM $63.77
- Revenue Next Year
- AGYS $22.41
- RYTM $44.91
- P/E Ratio
- AGYS $35.60
- RYTM N/A
- Revenue Growth
- AGYS 17.05
- RYTM 81.55
- 52 Week Low
- AGYS $74.03
- RYTM $35.17
- 52 Week High
- AGYS $142.64
- RYTM $68.58
- Technical
- Relative Strength Index (RSI)
- AGYS 39.38
- RYTM 43.02
- Support Level
- AGYS $124.72
- RYTM $52.71
- Resistance Level
- AGYS $135.59
- RYTM $60.12
- Average True Range (ATR)
- AGYS 5.28
- RYTM 2.13
- MACD
- AGYS -1.06
- RYTM -0.36
- Stochastic Oscillator
- AGYS 1.68
- RYTM 23.48
About AGYS Agilysys Inc. (DE)
Agilysys Inc has been a leader in hospitality software, delivering innovative cloud-native SaaS and on-premise solutions for hotels, resorts and cruise lines, casinos, corporate food service management, restaurants, universities, stadiums, and healthcare. The Company's software solutions include point-of-sale (POS), property management (PMS), inventory and procurement, payments, and related applications that manage and enhance the entire guest journey. Agilysys also is known for its world-class customer-centric service.
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in development and commercialization of therapies for patients with rare diseases. It is focused on the development and commercialization of peptide therapeutics for the treatment of gastrointestinal, or GI, diseases, and genetic deficiencies that result in metabolic disorders. The company's product candidate is setmelanotide (RM 493), which is a potent, melanocortin 4, or MC4, receptor agonist for the treatment of rare genetic disorders of obesity caused by MC4 pathway deficiencies. Geographically the company generates its revenue from the United states, Germany, and other with the majority being generated from the United states.